HUP0304093A2 - Daganatellenes hatású, egy mTOR gátlót és egy antimetabolit daganatellenes szert tartalmazó kombinációk és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Daganatellenes hatású, egy mTOR gátlót és egy antimetabolit daganatellenes szert tartalmazó kombinációk és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0304093A2
HUP0304093A2 HU0304093A HUP0304093A HUP0304093A2 HU P0304093 A2 HUP0304093 A2 HU P0304093A2 HU 0304093 A HU0304093 A HU 0304093A HU P0304093 A HUP0304093 A HU P0304093A HU P0304093 A2 HUP0304093 A2 HU P0304093A2
Authority
HU
Hungary
Prior art keywords
antineoplastic
pharmaceutical compositions
mtor inhibitor
antimetabolic
compositions containing
Prior art date
Application number
HU0304093A
Other languages
English (en)
Inventor
Gary Dukart
Jurgen Hermann Ernst Frisch
James Joseph Gibbons
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of HUP0304093A2 publication Critical patent/HUP0304093A2/hu
Publication of HUP0304093A3 publication Critical patent/HUP0304093A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0304093A 2001-04-06 2002-04-05 Antineoplastic combinations containing and mtor inhibitor and an antimetabolic antineoplastic agent and pharmaceutical compositions containing them HUP0304093A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28238501P 2001-04-06 2001-04-06
US28238801P 2001-04-06 2001-04-06
PCT/US2002/010912 WO2002080975A1 (en) 2001-04-06 2002-04-05 Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil

Publications (2)

Publication Number Publication Date
HUP0304093A2 true HUP0304093A2 (hu) 2004-04-28
HUP0304093A3 HUP0304093A3 (en) 2008-08-28

Family

ID=26961412

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0304093A HUP0304093A3 (en) 2001-04-06 2002-04-05 Antineoplastic combinations containing and mtor inhibitor and an antimetabolic antineoplastic agent and pharmaceutical compositions containing them

Country Status (22)

Country Link
EP (1) EP1385551B1 (hu)
JP (1) JP2004525950A (hu)
KR (1) KR100862178B1 (hu)
CN (1) CN1309421C (hu)
AT (1) ATE406892T1 (hu)
AU (1) AU2007242958A1 (hu)
BR (1) BR0208627A (hu)
CA (1) CA2442849A1 (hu)
DE (1) DE60228699D1 (hu)
EA (1) EA010184B1 (hu)
ES (1) ES2312568T3 (hu)
HK (1) HK1060062A1 (hu)
HU (1) HUP0304093A3 (hu)
IL (1) IL157898A0 (hu)
MX (1) MXPA03009092A (hu)
NO (1) NO20034433L (hu)
NZ (1) NZ540047A (hu)
PL (1) PL363991A1 (hu)
PT (1) PT1385551E (hu)
SG (1) SG152906A1 (hu)
SI (1) SI1385551T1 (hu)
WO (1) WO2002080975A1 (hu)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE399766T1 (de) 2000-10-20 2008-07-15 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische heterozyklen
NZ527692A (en) * 2001-02-19 2005-05-27 Novartis Ag Cancer treatment
GB0124577D0 (en) * 2001-10-12 2001-12-05 Novartis Forschungsstiftung Novel methods
CN100522967C (zh) 2002-02-01 2009-08-05 阿里亚德基因治疗公司 含磷化合物及其应用
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
JP2007525507A (ja) * 2004-02-26 2007-09-06 ザ ペン ステイト リサーチ ファンデーション オピオイド増殖因子レセプターを用いる、新生物の処置のための組み合わせ療法
WO2006027545A2 (en) * 2004-09-10 2006-03-16 Agency For Science, Technology And Research Method
ES2322175T3 (es) 2004-09-17 2009-06-17 EISAI R&D MANAGEMENT CO., LTD. Composicion medicinal con estabilidad mejorada y gelificacion reducida.
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
EP3488866A1 (en) * 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
CA2629714A1 (en) * 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of an mtor inhibitor to treat patients with cancer
ES2481671T3 (es) * 2005-11-21 2014-07-31 Novartis Ag Inhibidores de mTOR en el tratamiento de tumores endocrinos
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
EP1880723A1 (en) * 2006-07-14 2008-01-23 Novartis AG Combination of mTOR inhibitor and antifolate compound
EP1976530A1 (en) * 2006-01-12 2008-10-08 Novartis AG Combination of mtor inhibitor and antipolate compound
EP1996193A2 (en) 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
EP2004163B1 (en) * 2006-04-05 2014-09-17 Novartis Pharma AG Combination of everolimus and vinorelbine
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
US20090311249A1 (en) * 2006-06-02 2009-12-17 Luca Gianni Capecitabine Combination Therapy
EP2054061A4 (en) * 2006-08-02 2009-09-02 Ariad Pharma Inc COMBINATION THERAPY
JP5368096B2 (ja) 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌に対する抗腫瘍剤
EP2087113A2 (en) * 2006-10-11 2009-08-12 Fusion Antibodies Limited Combination therapy
CA2669415A1 (en) 2006-11-14 2008-05-22 Ariad Pharmaceuticals, Inc. Solid dosage form comprising ap23573
CA2675736A1 (en) 2007-01-19 2008-07-24 Eisai R&D Management Co., Ltd. Composition for treatment of pancreatic cancer
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
HUE039497T2 (hu) * 2007-03-07 2019-01-28 Abraxis Bioscience Llc Rapamicin rákellenes szert és albumint tartalmazó nanorészecske
PT2155188E (pt) 2007-06-01 2013-12-19 Abraxis Bioscience Llc Métodos e composições para o tratamento de cancro recorrente
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
RU2492860C2 (ru) 2008-06-17 2013-09-20 УАЙТ ЭлЭлСи Антиопластические комбинации, содержащие нкi-272 и винорелбин
PL3175853T3 (pl) 2008-08-04 2024-03-25 Wyeth Llc Przeciwnowotworowe połączenia neratynibu i kapecytabiny
PL3000467T3 (pl) 2009-04-06 2023-05-02 Wyeth Llc Schemat leczenia wykorzystujący neratynib dla raka sutka
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
ES2687968T3 (es) 2013-05-14 2018-10-30 Eisai R&D Management Co., Ltd. Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
EP4089076A1 (en) 2014-08-28 2022-11-16 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
KR20170122734A (ko) 2015-02-25 2017-11-06 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 고미 억제 방법
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
KR20180018695A (ko) 2015-06-16 2018-02-21 가부시키가이샤 프리즘 파마 항암제
RS65129B1 (sr) 2016-03-28 2024-02-29 Incyte Corp Jedinjenja pirolotriazina kao inhibitori tam
WO2020006408A1 (en) 2018-06-29 2020-01-02 Incyte Corporation Formulations of an axl/mer inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6384019B1 (en) * 1997-01-24 2002-05-07 Norsk Hydro Asa Gemcitabine derivatives
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
HUP0304093A3 (en) 2008-08-28
BR0208627A (pt) 2004-03-09
HK1060062A1 (en) 2004-07-30
EA010184B1 (ru) 2008-06-30
NO20034433L (no) 2003-11-25
NZ540047A (en) 2007-01-26
EA200301091A1 (ru) 2004-02-26
SG152906A1 (en) 2009-06-29
PT1385551E (pt) 2008-11-03
ATE406892T1 (de) 2008-09-15
EP1385551A1 (en) 2004-02-04
KR20040007491A (ko) 2004-01-24
DE60228699D1 (de) 2008-10-16
MXPA03009092A (es) 2004-02-12
CN1309421C (zh) 2007-04-11
CA2442849A1 (en) 2002-10-17
NO20034433D0 (no) 2003-10-03
IL157898A0 (en) 2004-03-28
KR100862178B1 (ko) 2008-10-09
EP1385551B1 (en) 2008-09-03
WO2002080975A1 (en) 2002-10-17
CN1545419A (zh) 2004-11-10
SI1385551T1 (sl) 2008-12-31
JP2004525950A (ja) 2004-08-26
AU2007242958A1 (en) 2008-01-10
PL363991A1 (en) 2004-11-29
ES2312568T3 (es) 2009-03-01

Similar Documents

Publication Publication Date Title
HUP0304093A3 (en) Antineoplastic combinations containing and mtor inhibitor and an antimetabolic antineoplastic agent and pharmaceutical compositions containing them
HUP0303325A3 (en) Pharmaceutical salts and pharmaceutical compositions containing them
HUP0400114A3 (en) N-benzoyl-benzenesulfonamid derivatives as antitumor agents and pharmaceutical compositions containing them
IL157741A0 (en) Pharmaceutical compositions containing an antihyperplastic active agent
IL161616A0 (en) Indazolypyrrolotriazine derivatives and pharmaceutical compositions containing the same
IL156716A0 (en) Pharmaceutical formulation
IL158300A0 (en) Bisarylimidazol derivatives and pharmaceutical compositions containing the same
IL158044A0 (en) Cyclopropylindole derivatives and pharmaceutical compositions containing the same
HUP0400974A3 (en) Peptide-based compounds and pharmaceutical compositions containing them
HUP0401333A3 (en) Spiropyrazole compounds and pharmaceutical compositions containing them
PT1461039E (pt) Composições farmacêuticas compreendendo cilostazol e um inibidor da captação de adenosina
IL156812A0 (en) Phthalazinone-piperidino derivatives and pharmaceutical compositions containing the same
GB0111597D0 (en) Pharmaceutical compositions
GB0118689D0 (en) Pharmaceutical formulation
HUP0303998A3 (en) Phthalazinones derivatives and pharmaceutical compositions containing them
PL366432A1 (en) Pharmaceutical formulation
IL159591A0 (en) Pharmaceutical compositions containing terbinafin and use thereof
IL158236A0 (en) Pharmaceutical compositions containing azithromycin and derivatives thereof
GB0108470D0 (en) Pharmaceutical compositions and their use
IL159006A0 (en) Phenoxy-phenyl derivatives and pharmaceutical compositions containing the same
IL161306A0 (en) Pharmaceutical formulation comprising (r)-bicalutamide
HK1068277A1 (en) Pharmaceutical compositions comprising chelidonineor derivatives thereof
AU2002252981A1 (en) Pharmaceutical compositions containing beta-mimetic agents and having few side-effects
IL153176A (en) Phenylpiperazines and pharmaceutical compositions comprising them
GB2382302B (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees